← ANALYST RATINGS · TIPRANKS
Axsome Therapeutics (AXSM): analyst forecast and price target
Analyst consensus
Strong Buy16 Buy1 Hold0 Sell
Ratings of 17 analysts in the last 3 months12-month forecast
Based on 17 price targets given in the last 3 months, the average target is $286, the highest $380, the lowest $247. The average is +81.9% from the last price of $157.
Analyst ratings 22
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $174 → $170−2.3% | Hold | +8.2% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $173 → $169−2.3% | Hold | +7.5% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $168 → $164−2.4% | Hold | +4.4% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $168 → $165−1.8% | Hold | +5.0% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $178 → $174−2.2% | Hold | +10.7% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $168 → $165−1.8% | Hold | +5.0% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| Unknown Analyst | UBS | $280 → $256−8.6% | Buy | +62.9% | Reiterated | 15.10.26on TipRanks 23:05 | −1.8% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $268 | Buy | +70.5% | Reiterated | 15.10.26on TipRanks 07:30 | −0.5%next day −1.8% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $295 | Buy | +87.7% | Reiterated | 14.10.26on TipRanks 07:25 | +4.9%next day −0.5% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $310 | Buy | +97.3% | Reiterated | 12.10.26on TipRanks 09:00 | −1.3%next day −5.8% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $276 | Buy | +75.6% | Reiterated | 09.10.26on TipRanks 09:10 | −1.6%next day −1.3% · 5 days −4.7% | ↗ |
| Matthew Hershenhorn★★★★★★★★★★#4544 · hits 100% · avg +85.8% | Oppenheimer | $280 | Buy | +78.2% | Reiterated | 06.10.26on TipRanks 08:30 | −2.1%next day −0.5% · 5 days −10.2% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $256 | Buy | +62.9% | Assigned | 01.10.26on TipRanks 07:10 | −1.4%next day −2.3% · 5 days −7.9% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $280 → $267−4.6% | Buy | +69.9% | Reiterated | 29.09.26on TipRanks 09:11 | −3.8%next day −0.7% · 5 days −8.3% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $247 | Hold | +57.2% | Reiterated | 25.09.26on TipRanks 08:25 | −1.0%next day +0.1% · 5 days −7.9% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $290 | Buy | +84.5% | Reiterated | 25.09.26on TipRanks 07:07 | −1.0%next day +0.1% · 5 days −7.9% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $200 → $285+42.5% | Buy | +81.4% | Initiated | 23.09.26on TipRanks 07:55 | −4.0%next day +1.4% · 5 days −4.0% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $258 | Buy | +64.2% | Reiterated | 18.09.26on TipRanks 07:10 | −3.2%next day −2.7% · 5 days −7.4% | ↗ |
| Malcolm Hoffman★★★★★★★★★★#7666 · hits 100% · avg +34.9% | BMO Capital | $310 | Buy | +97.3% | Reiterated | 14.09.26on TipRanks 07:40 | −1.4%next day −5.3% · 5 days −7.0% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $316 | Buy | +101.1% | Reiterated | 11.09.26on TipRanks 13:10 | +3.7%next day −1.4% · 5 days −5.8% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $380 | Buy | +141.8% | Reiterated | 11.08.26on TipRanks 10:55 | −2.0%next day −0.8% · 5 days +0.4% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $260 → $275+5.8% | Buy | +75.0% | Reiterated | 10.08.26on TipRanks Aug 11 06:55 | +3.9%next day −2.0% · 5 days −2.0% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | $300 → $315+5.0% | Buy | +100.5% | Reiterated | 10.08.26on TipRanks 12:50 | +3.9%next day −2.0% · 5 days −2.0% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 10.08.26on TipRanks 09:07 | +3.9%next day −2.0% · 5 days −2.0% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $241 → $246+2.1% | Buy | +56.5% | Reiterated | 05.05.26on TipRanks 06:35 | −1.1%next day −1.6% · 5 days −1.6% | ↗ |
| Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% | Cantor Fitzgerald | $234 → $272+16.2% | Buy | +73.1% | Reiterated | 04.05.26on TipRanks 12:05 | +8.7%next day −1.1% · 5 days −6.2% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $251 → $259+3.2% | Buy | +64.8% | Assigned | 10.04.26on TipRanks 06:25 | −0.4%next day −0.9% · 5 days +1.6% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $230 | Buy | +46.4% | Initiated | 23.02.26on TipRanks 17:30 | −3.5%next day −4.2% · 5 days −2.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Axsome Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $289 at a price of $184 (+56.5%); now: $286 at $157 (+81.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 2 | 2 | 8 |
| Buy | 36 | 38 | 35 | 29 | 33 | 25 |
| Hold | 2 | 2 | 2 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 02.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.60 (from $-1.00 to $-0.21). Last quarter: $-0.99.
Sales
Next quarter’s sales estimate — $251M (from $228M to $262M). Last quarter: $218M.
Best top-analyst consensus in the sector · Healthcare
About Axsome Therapeutics
- CEO: Herriot Tabuteau
- Employees: 1,346
- One World Trade Center, New York City, NY, 10007, US
- www.axsome.com
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Data from the stock’s TipRanks forecast page, read 40 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗